PDL1 Monoclonal Antibody-Modified mPEG–PLGA-NH2 Nanocomposite Loaded with Heterophyllin B for the Treatment of Gastric Cancer
Authors:
- 23 July 2025
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (15) , 16518-16527
Abstract
Immune checkpoint inhibitors (ICIs) show effectiveness in gastric cancer (GC) treatment, yet enhancing their efficacy remains challenging. We encapsulated the anticancer compound Heterophyllin B (HB) in mPEG-PLGA-NH2 nanoparticles (NPs), modified with αPDL1, forming mPEG-PLGA-NH2@HB-αPDL1 NPs. These NPs displayed low toxicity to GES-1 cells and good blood compatibility. They effectively inhibited GC cell malignant phenotypes and downregulated PD-L1 expression via the PI3K/AKT pathway. In GC allograft mice, the HB and αPDL1 combination therapy outperformed monotherapy, with the NPs showing better efficacy than free drugs. Additionally, the NPs improved the tumor immune microenvironment. H&E staining confirmed no significant toxicity to major mouse organs. Thus, mPEG-PLGA-NH2@HB-αPDL1 offers a promising strategy for optimizing ICI therapy in GC treatment.Keywords
Funding Information
- Medical Science and Technology Project of Zhejiang Province (GZY-ZJ-KJ-23094)
- Zhejiang Province Public Welfare Technology Application Research Project (LGF21H030002)
- Zhejiang Chinese Medical University (2023FSYYZZ15)
This publication has 27 references indexed in Scilit:
- Cuproptosis Induced by ROS Responsive Nanoparticles with Elesclomol and Copper Combined with αPD‐L1 for Enhanced Cancer ImmunotherapyAdvanced Materials, 2023
- Heterophyllin B inhibits the malignant phenotypes of gastric cancer cells via CXCR4Human Cell, 2022
- Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humansJCSM Rapid Communications, 2021
- Gastric cancerThe Lancet, 2020
- Current status of immune checkpoint inhibitors for gastric cancerGastric Cancer, 2020
- A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update dataGastric Cancer, 2019
- Combination therapy with PD-1 or PD-L1 inhibitors for cancerInternational Journal of Clinical Oncology, 2019
- Burden of Gastric CancerClinical Gastroenterology and Hepatology, 2019
- Fatal Toxic Effects Associated With Immune Checkpoint InhibitorsJAMA Oncology, 2018
- LC‐ESI‐MS/MS analysis and pharmacokinetics of heterophyllin B, a cyclic octapeptide from Pseudostellaria heterophylla in rat plasmaBiomedical Chromatography, 2015